OBJECTIVES: To assess the in vitro activity of the FDA-approved antihelminthic drug pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis. METHODS: A head-to-head comparison of a standard radiolabelled thymidine incorporation assay and the SYBR Green I-based fluorescence assay for determination of in vitro inhibition by pyrvinium and metronidazole was performed. RESULTS: The 50% inhibitory concentration (IC(50)) for treatment of E. histolytica with pyrvinium was 4-5 microM for both assays compared with 1-2 microM for metronidazole. For pyrvinium treatment of G. intestinalis, an IC(50) of approximately 12 microM was determined by the radiolabelled thymidine assay alone, with maximum inhibition around 60%. In contrast, the IC(50) for metronidazole treatment using this assay was approximately 2 microM. CONCLUSIONS: Pyrvinium is a potential gut lumen agent for treatment of intestinal amoebiasis, but possibly not for giardiasis. SYBR Green I is an alternative screening method for E. histolytica, but not G. intestinalis.
OBJECTIVES: To assess the in vitro activity of the FDA-approved antihelminthic drug pyrvinium pamoate against Entamoeba histolytica and Giardia intestinalis. METHODS: A head-to-head comparison of a standard radiolabelled thymidine incorporation assay and the SYBR Green I-based fluorescence assay for determination of in vitro inhibition by pyrvinium and metronidazole was performed. RESULTS: The 50% inhibitory concentration (IC(50)) for treatment of E. histolytica with pyrvinium was 4-5 microM for both assays compared with 1-2 microM for metronidazole. For pyrvinium treatment of G. intestinalis, an IC(50) of approximately 12 microM was determined by the radiolabelled thymidine assay alone, with maximum inhibition around 60%. In contrast, the IC(50) for metronidazole treatment using this assay was approximately 2 microM. CONCLUSIONS:Pyrvinium is a potential gut lumen agent for treatment of intestinal amoebiasis, but possibly not for giardiasis. SYBR Green I is an alternative screening method for E. histolytica, but not G. intestinalis.
Authors: Jacob D Johnson; Richard A Dennull; Lucia Gerena; Miriam Lopez-Sanchez; Norma E Roncal; Norman C Waters Journal: Antimicrob Agents Chemother Date: 2007-03-19 Impact factor: 5.191
Authors: V Lemée; I Zaharia; G Nevez; M Rabodonirina; P Brasseur; J J Ballet; L Favennec Journal: J Antimicrob Chemother Date: 2000-11 Impact factor: 5.790
Authors: Emma L Gunderson; Clifford Bryant; Christina A Bulman; Chelsea Fischer; Mona Luo; Ian Vogel; Kee-Chong Lim; Shabnam Jawahar; Nancy Tricoche; Denis Voronin; Christopher Corbo; Rene B Ayiseh; Faustin P T Manfo; Glory E Mbah; Fidelis Cho-Ngwa; Brenda Beerntsen; Adam R Renslo; Sara Lustigman; Judy A Sakanari Journal: Pharmaceuticals (Basel) Date: 2022-02-02
Authors: Snigdha Tiash; Jake Saunders; Christopher J S Hart; John H Ryan; Andrew G Riches; Tina S Skinner-Adams Journal: Int J Parasitol Drugs Drug Resist Date: 2020-03-13 Impact factor: 4.077